BR102020019867A2 - Use of avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2 - Google Patents

Use of avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2

Info

Publication number
BR102020019867A2
BR102020019867A2 BR102020019867A BR102020019867A BR102020019867A2 BR 102020019867 A2 BR102020019867 A2 BR 102020019867A2 BR 102020019867 A BR102020019867 A BR 102020019867A BR 102020019867 A BR102020019867 A BR 102020019867A BR 102020019867 A2 BR102020019867 A2 BR 102020019867A2
Authority
BR
Brazil
Prior art keywords
ibv
cov
sars
covid
virus
Prior art date
Application number
BR102020019867A
Other languages
Portuguese (pt)
Inventor
Izabel Florindo Guedes Maria
Fraga Van Tilburg Mauricio
De Carvalho Almeida Ney
Original Assignee
Fundacao Univ Estadual Do Ceara Funece
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Univ Estadual Do Ceara Funece filed Critical Fundacao Univ Estadual Do Ceara Funece
Priority to BR102020019867A priority Critical patent/BR102020019867A2/en
Priority to PCT/BR2021/050410 priority patent/WO2022061439A1/en
Publication of BR102020019867A2 publication Critical patent/BR102020019867A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

uso da vacina de coronavírus aviário (ibv) como modelo de imunização em mamíferos contra sars-cov 2. provocada por um vírus recém descoberto da família coronaviridae, o então denominado sars - cov 2, causador da atual pandemia de coronavirose (covid-19), gera uma síndrome respiratória aguda grave como principal processo patológico. curiosamente, o coronavírus aviário (ibv) causador da bronquite infecciosa das galinhas (big), que é um enfermidade com certo grau de semelhança com o covid-19, chamou-nos atenção por ser um vírus há muito tempo estudado, na qual há relatos na literatura científica mundial de indivíduos que quando em contato com ele geraram anticorpos e nunca desenvolveram a doença das galinhas nem qualquer outra semelhante. a utilização de vacinas obtidas de agentes etiológicos de origem animal não é nova, vide a vacina para varíola feita por jenner no final do século xviii que imunizou populações humanas utilizando vírus da varíola de bovinos. assim, a presente invenção refere-se à possibilidade de segundo uso do ibv, em qualquer estado (morto, atenuado, com apenas suas estruturas moleculares isoladas ou associadas), na imunização (vacina) de mamíferos, inclusive humanos, contra o sars-cov 2, seja ela humoral ou celular. os estudos em camundongos imunizados com o ibv mostraram satisfatória atividade da ação neutralizante/inibitória dos anticorpos por eles produzidos contra o vírus sars-cov 2 em cultivo de células, denotando que anticorpos anti-ibv funcionam também na proteção contra o covid-19, podendo-se usar vacinas contra o ibv das aves também como vacinas contra a covid-19.use of the avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2. caused by a newly discovered virus of the coronaviridae family, the so-called sars - cov 2, which causes the current coronavirus pandemic (covid-19) , generates a severe acute respiratory syndrome as the main pathological process. curiously, the avian coronavirus (ibv) that causes infectious bronchitis in chickens (big), which is a disease with a certain degree of similarity to covid-19, caught our attention because it is a virus that has been studied for a long time, in which there are reports in the world scientific literature of individuals who, when in contact with it, generated antibodies and never developed chicken disease or any other similar disease. the use of vaccines obtained from etiological agents of animal origin is not new, see the smallpox vaccine made by jenner at the end of the 18th century who immunized human populations using bovine smallpox virus. thus, the present invention refers to the possibility of the second use of ibv, in any state (dead, attenuated, with only its isolated or associated molecular structures), in the immunization (vaccine) of mammals, including humans, against sars-cov 2, whether humoral or cellular. studies in mice immunized with ibv showed satisfactory activity of the neutralizing/inhibitory action of the antibodies produced by them against the sars-cov 2 virus in cell culture, denoting that anti-ibv antibodies also work in the protection against covid-19, being able to - if you use vaccines against the ibv of birds also as vaccines against covid-19.

BR102020019867A 2020-09-28 2020-09-28 Use of avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2 BR102020019867A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR102020019867A BR102020019867A2 (en) 2020-09-28 2020-09-28 Use of avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2
PCT/BR2021/050410 WO2022061439A1 (en) 2020-09-28 2021-09-27 Use of the infectious bronchitis virus (ibv), vaccine for immunizing mammals against coronavirus and method for immunizing mammals against coronavirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102020019867A BR102020019867A2 (en) 2020-09-28 2020-09-28 Use of avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2

Publications (1)

Publication Number Publication Date
BR102020019867A2 true BR102020019867A2 (en) 2022-04-12

Family

ID=80844471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102020019867A BR102020019867A2 (en) 2020-09-28 2020-09-28 Use of avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2

Country Status (2)

Country Link
BR (1) BR102020019867A2 (en)
WO (1) WO2022061439A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073856A1 (en) * 1981-08-28 1983-03-16 Gist-Brocades N.V. Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain
GB201601498D0 (en) * 2016-01-27 2016-03-09 Pirbright Inst The Coronavirus

Also Published As

Publication number Publication date
WO2022061439A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
Francis Jr et al. Immunological studies with the virus of influenza
Abdelwhab et al. Introduction and enzootic of A/H5N1 in Egypt: Virus evolution, pathogenicity and vaccine efficacy ten years on
Paniker et al. Infection with A2 Hong Kong influenza virus in domestic cats
WO2016192670A1 (en) Live-attenuated virus and methods of production and use
KR100850545B1 (en) A novel canine influenza virus and vaccine therefore
Jensen New set of type A influenza viruses
BR9801015A (en) Surface antigen vaccine against influenza, and, process for the preparation of surface antigen proteins from influenza viruses prepared in an animal cell culture.
Shope Serological evidence for the occurrence of infection with human influenza virus in swine
Nakayama et al. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine
WO2007032376A1 (en) SECRETORY IgA AND IgG ANTIBODIES-INDUCING AGENT
BR102020019867A2 (en) Use of avian coronavirus vaccine (ibv) as a model of immunization in mammals against sars-cov 2
Jennings et al. The immune response of hamsters to purified haemagglutinins and whole influenza virus vaccines following live influenza virus infection
WO2017129048A1 (en) Vaccine used for preventing and treating influenza, avian influenza and upper respiratory tract infection
FUKUMI et al. Studies on Sendai virus infection in laboratory mice
CN102203134A (en) Vaccine compositions
CN101112617A (en) Method for making new, branch and flow H9 sub-type tri-combined inactived vaccine
Shope Immunological relationship between the swine and human influenza viruses in swine
Tamura et al. Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice
McCarthy et al. An Investigation of immunological relationships between the viruses of variola, vaccinia, cowpox and ectromelia by neutralization tests on the chorio-allantois of chick embryos
PT833903E (en) Multivalent Bovine Coroanavirus Vaccine and Method for Treating Influenza Decoronaviruses of Bovine
Kilbourne A virologist's perspective on the 1918–19 pandemic
CN113747915A (en) Optimized vaccine compositions and methods of making the same
JP3109886B2 (en) Nasal vaccine
Honda-Okubo et al. An Advax-CpG55. 2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice
CN106029686B (en) Monovalent H5 vaccine

Legal Events

Date Code Title Description
B11K Dismissal acc. art. 17, par 2 of ipl - pending earlier application (priority claim) definitively shelved

Free format text: 11.11 ? PRIORIDADE INTERNA: BR 10 2021 019285 2

B03F Publication of an application: publication of application definitely dismissed [chapter 3.6 patent gazette]